Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KIF11 | P52732 | 2/20 | 0.47 |
| ▸ | TRPV3 | Q8NET8 | 1/20 | 0.45 |
| ▸ | S1PR1 | P21453 | 1/20 | 0.44 |
| ▸ | S1PR3 | Q99500 | 1/20 | 0.44 |
| ▸ | TOP1 | P11387 | 2/20 | 0.44 |
| ▸ | GABRA1 | P14867 | 1/20 | 0.43 |
| ▸ | GABRG2 | P18507 | 1/20 | 0.43 |
| ▸ | GABRB3 | P28472 | 1/20 | 0.43 |
| ▸ | GABRA3 | P34903 | 1/20 | 0.43 |
| ▸ | IDO1 | P14902 | 1/20 | 0.42 |
| ▸ | TDO2 | P48775 | 1/20 | 0.42 |
| ▸ | ALOX5 | P09917 | 1/20 | 0.41 |
| ▸ | MAPT | P10636 | 2/20 | 0.41 |
| ▸ | L3MBTL1 | Q9Y468 | 2/20 | 0.41 |
| ▸ | KMO | O15229 | 2/20 | 0.40 |
| ▸ | TRPV1 | Q8NER1 | 1/20 | 0.40 |
| ▸ | MEN1 | O00255 | 3/20 | 0.40 |
| ▸ | KMT2A | Q03164 | 3/20 | 0.40 |
| ▸ | NPC1 | O15118 | 2/20 | 0.40 |
| ▸ | RAB9A | P51151 | 2/20 | 0.40 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4455134 | 0.84 | KMO (0.44) | S1PR1S1PR3GABRA1GABRG2GABRB3 | |
| SCHEMBL3565439 | 0.84 | SYK (0.42) | TRPV3S1PR1S1PR3TOP1GABRA1 | |
| SCHEMBL3560875 | 0.84 | KDM4E (0.46) | S1PR1S1PR3TOP1GABRA1GABRG2 | |
| SCHEMBL12616652 | 0.82 | KMO (0.46) | TRPV3IDO1TDO2MAPTL3MBTL1 | |
| SCHEMBL28267570 | 0.81 | MEN1 (0.54) | KIF11TRPV3S1PR1S1PR3TOP1 | |
| SCHEMBL446173 | 0.81 | MEN1 (0.58) | TRPV3ALOX5MAPTL3MBTL1KMO | |
| SCHEMBL3563087 | 0.80 | IDO1 (0.39) | KIF11TRPV3S1PR1S1PR3TOP1 | |
| SCHEMBL21327010 | 0.79 | CHRNA7 (0.47) | TRPV3GABRA1GABRG2GABRB3GABRA3 | |
| SCHEMBL7210451 | 0.79 | NPC1 (0.47) | GABRA1GABRG2GABRB3GABRA3MAPT | |
| SCHEMBL441888 | 0.79 | MAPT (0.59) | MAPTL3MBTL1KMOMEN1KMT2A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 38 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-118047763-A | Saturated nitrogen heterocyclic compound containing pyrimidine structure, and preparation method and application thereof | 贵州大学 | 2024-05-17 | — | — | CN | disclosed |
| EP-3106464-A1 | NOVEL COMPOUNDS | Convergence Pharmaceuticals Limited (GB) | 2016-12-21 | — | — | EP | disclosed |
| EP-2861594-B1 | NOVEL COMPOUNDS | CONVERGENCE PHARMACEUTICALS (GB) | 2016-08-24 | — | — | EP | disclosed |
| US-20160184306-A1 | Novel Pyrimidinyl-DiazoSpiro Compounds | Convergence Pharmaceuticals Limited (GB) | 2016-06-30 | — | — | US | disclosed |
| EP-2379535-B1 | 7-PHENOXYCHROMAN CARBOXYLIC ACID DERIVATIVES | ARRAY BIOPHARMA INC (US) | 2016-06-15 | — | — | EP | disclosed |
| US-9309254-B2 | Pyrimidinyl-diazospiro compounds | Convergence Pharmaceuticals Limited (GB) | 2016-04-12 | — | — | US | disclosed |
| US-20150119404-A1 | NOVEL COMPOUNDS | CONVERGANCE PHARMACEUTICALS LIMITED (GB) | 2015-04-30 | — | — | US | disclosed |
| EP-2861594-A1 | NOVEL COMPOUNDS | Convergence Pharmaceuticals Limited (GB) | 2015-04-22 | — | — | EP | disclosed |
| US-9012651-B2 | TRPV3 modulators | ABBVIE INC. (US) | 2015-04-21 | — | — | US | disclosed |
| EP-2613775-B1 | N-HYDROXY-BENZAMIDES FOR THE TREATMENT OF CANCER | HOFFMANN LA ROCHE (CH) | 2014-07-30 | — | — | EP | disclosed |
| US-7332511-B2 | Vanilloid receptor ligands and their use in treatments | AMGEN INC. (US) | 2008-02-19 | — | — | US | disclosed |
| US-7148221-B2 | Vanilloid receptor ligands and their use in treatments | AMGEN INC. (US) | 2006-12-12 | — | — | US | disclosed |
| US-7144888-B2 | Vanilloid receptor ligands and their use in treatments | AMGEN INC. (US) | 2006-12-05 | — | — | US | disclosed |
| EP-1717220-A2 | Vanilloid receptor ligands and their use in treatments | Amgen, Inc (US) | 2006-11-02 | — | — | EP | disclosed |
| EP-1688408-A2 | Vanilloid receptor ligands and their use in treatments | Amgen, Inc (US) | 2006-08-09 | — | — | EP | disclosed |
| US-20050277631-A1 | Vanilloid receptor ligands and their use in treatments | AMGEN INC. | 2005-12-15 | — | — | US | disclosed |
| US-20050272777-A1 | Vanilloid receptor ligands and their use in treatments | AMGEN INC. | 2005-12-08 | — | — | US | disclosed |
| EP-1546116-A1 | VANILLOID RECEPTOR LIGANDS AND THEIR USE IN TREATMENTS | Amgen Inc. (US) | 2005-06-29 | — | — | EP | disclosed |
| US-20040082780-A1 | Vanilloid receptor ligands and their use in treatments | AMGEN, INC. | 2004-04-29 | — | — | US | disclosed |
| WO-2004014871-A1 | VANILLOID RECEPTOR LIGANDS AND THEIR USE IN TREATMENTS | AMGEN INC. (US) | 2004-02-19 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20160184306-A1 | Novel Pyrimidinyl-DiazoSpiro Compounds | TRPV1, KCNJ2, KCNN2 | KIF11 4014/4885TRPV3 19/4885S1PR1 401/4885 |
| US-20050272777-A1 | Vanilloid receptor ligands and their use in treatments | TRPV1, TRPV2, TRPV3 | KIF11 2278/4885TRPV3 3/4885S1PR1 1267/4885 |
| US-20050277631-A1 | Vanilloid receptor ligands and their use in treatments | TRPV1, TRPV2, TRPV3 | KIF11 2278/4885TRPV3 3/4885S1PR1 1267/4885 |
| US-20150119404-A1 | NOVEL COMPOUNDS | KCNJ2, KCNN3, KCNN2 | KIF11 3592/4885TRPV3 13/4885S1PR1 407/4885 |
| US-20040082780-A1 | Vanilloid receptor ligands and their use in treatments | TRPV1, TRPV2, TRPV3 | KIF11 2444/4885TRPV3 3/4885S1PR1 1132/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.